Travere Therapeutics (TVTX) Assets (2011 - 2026)

Travere Therapeutics has reported Assets for 16 years, with the latest figure at $555.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 1.16% year-over-year to $555.2 million; the trailing twelve-month figure through Mar 2026 stood at $555.2 million (up 1.16% YoY), and the FY2025 full-year result was $605.2 million, up 1.86% from the prior year.
• Assets for Q1 2026 stood at $555.2 million, down from $605.2 million in the prior quarter.
• The five-year high for Assets was $832.8 million in Q3 2023, with the low at $504.4 million in Q3 2024.
• Historically, Assets has averaged $664.1 million across 5 years, with a median of $663.5 million in 2024.
• Annual changes were most pronounced in 2023 — Assets advanced 17.3% — and 2024, when it sank 39.44%.
• Travere Therapeutics' Assets stood at $672.6 million in 2022, then grew by 17.3% to $788.9 million in 2023, then fell by 24.69% to $594.1 million in 2024, then increased by 1.86% to $605.2 million in 2025, then dropped by 8.26% to $555.2 million in 2026.
• The last three Assets figures came in at $555.2 million (Q1 2026), $605.2 million (Q4 2025), and $538.6 million (Q3 2025), per Business Quant data.